The company plans to show new data for its Signatera oncology test at three upcoming conferences this year, including in breast cancer and bladder cancer.
Startup Prophet Genomics plans to commercialize the assay, dubbed Urine Exfoliated Cells Copy Number Aberration Detector, for early detection and monitoring of patients.
The firm expects to launch a 510(k)-cleared version of its Bladder EpiCheck recurrence assay early next year followed by an RUO early-stage lung cancer assay.
The platform was used to subtype patients in a Phase II trial and found that patients in the claudin-low subgroup had the best two-year progression-free survival on pembrolizumab.
The firm recently published a study describing three assays for prostate cancer and reporting their sensitivity and specificity in case-control cohort.
